Scarica l'app Stockscreener
12.44
5.25%
0.64
Precedente Chiudi:
$11.80
Aprire:
$12
Volume 24 ore:
60,583
Relative Volume:
0.27
Capitalizzazione di mercato:
$493.84M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.79%
1M Prestazione:
+5.52%
6M Prestazione:
-37.81%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.81
$12.64
Intervallo di 1 settimana:
$10.83
$12.64
Portata 52W:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Confronta ORKA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
12.45 | 493.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.73 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.74 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.88 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.94 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Squarepoint Ops LLC Acquires New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial - MSN
Oruka Therapeutics Holds Annual Stockholders Meeting - TipRanks
Jane Street Group LLC Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Northern Trust Corp Acquires Shares of 64,044 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright maintains Buy on Oruka stock, $45 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Oruka stock, $45 target - Investing.com UK
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at BTIG Research - Defense World
BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target - marketscreener.com
BTIG sets $44 price target on Oruka Therapeutics stock - Investing.com UK
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Oruka Therapeutics begins trial for psoriasis treatment By Investing.com - Investing.com South Africa
Oruka Therapeutics begins trial for psoriasis treatment - Investing.com Australia
Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment - marketscreener.com
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewswire
Revolutionary Psoriasis Treatment Begins Human Trials: Only 2-3 Doses Per Year Needed - Stock Titan
Wedbush Forecasts Reduced Earnings for Oruka Therapeutics - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) versus Trinity Biotech (NASDAQ:TRIB) Critical Analysis - Defense World
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics Announces Accelerated Clinical Timelines and Strong Financial Position for Psoriasis Programs - Nasdaq
Oruka Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Oruka Therapeutics, Inc. SEC 10-Q Report - TradingView
Oruka Therapeutics (NASDAQ:ORKA) and Trinity Biotech (NASDAQ:TRIB) Head-To-Head Analysis - Defense World
JPMorgan Chase & Co. Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Barclays PLC Purchases Shares of 74,583 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Issues Negative Estimate for ORKA Earnings - Defense World
Equities Analysts Offer Predictions for ORKA Q1 Earnings - Defense World
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference - GlobeNewswire
Geode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday - Defense World
Vanguard Group Inc. Purchases 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - The AM Reporter
Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Acquired by Wellington Management Group LLP - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Charles Schwab Investment Management Inc. Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Non sono disponibili dati finanziari per Oruka Therapeutics Inc (ORKA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Oruka Therapeutics Inc Azioni (ORKA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Aug 16 '24 |
Buy |
2.93 |
5,818 |
17,067 |
2,117,213 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
1.04%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):